Leidos and biopharmaceutical company Immunovaccine have expanded a partnership to develop peptide-based vaccines against malaria. The U.S. Agency for International Development and Leidos selected a vaccine delivery formulation based on Immunovaccine’s DepoVax platform for further research and development through a contract extension, Immunovaccine said Tuesday. USAID issued the new contract after the two companies completed various milestones under the Leidos […] More

Leidos and Canada-based clinical vaccine developer Immunovaccine have forged an agreement to jointly develop a preventive agent against the mosquito-borne Zika virus in an effort to halt the spread of the disease that has affected much of Latin America within the past year. The companies said Thursday Immunovaccine will use its DepoVax platform to create an anti-Zika vaccine and […] More